Misoprostol For Nulliparous Women Before Hysteroscopy

Comparison of Vaginal Versus Oral Misoprostol for Nulliparous Women Prior to Operative Hysteroscopy

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01156948

Enrollment

120

Registered

2010-07-05

Start date

2008-05-31

Completion date

2011-12-31

Last updated

2010-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Ripening

Keywords

misoprostol, nulliparous, hysteroscopy

Brief summary

To compare the impact of 400-microgram self-administered vaginal versus self-administered oral misoprostol at home on preoperative cervical ripening in nulliparous women prior to outpatient hysteroscopy.

Detailed description

There is no consensus on the effect of misoprostol on cervical ripening for nulliparous women. The aim of the study is to compare the impact of 400-microgram self-administered vaginal versus self-administered oral misoprostol at home on preoperative cervical ripening in nulliparous women prior to outpatient hysteroscopy.

Interventions

DRUGmisoprostol

400ug vaginally the day before surgery

DRUGoral misoprostol

400ug misoprostol orally the day before the surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

16 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* nulliparous women who are referred to outpatient hysteroscopy and who have given informed consent will be eligible for study recruitment.

Exclusion criteria

* women with a known allergy to misoprostol.

Design outcomes

Primary

Measure	Time frame
cervical width	one day

Secondary

Measure	Time frame
side effects	one day

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026